Edwards Lifesciences raised its full-year sales and adjusted earnings per share guidance for 2016 after posting increases in sales and earnings during the quarter that ended on June 30.

Led by strong sales growth in its atrial fibrillation and heart failure divisions, St. Jude Medical’s second quarter sales increased 11 percent to $1.56 billion compared with the same period last year. The quarter ended July 2.

The Centers for Medicare & Medicaid Services (CMS) announced on July 25 a five-year proposed bundled payments model for hospitals that treat Medicare patients following an MI or bypass surgery. CMS also announced a proposed five-year cardiac rehabilitation incentive payment model to encourage hospitals to refer patients to cardiac rehabilitation.

For the second quarter of fiscal year 2016, Abbott’s sales increased 3.2 percent to $5.33 billion, while its net earnings decreased 21.5 percent compared with the same period of 2015.

Madrigal Pharmaceuticals and Synta Pharmaceuticals completed their merger on July 22.

Theranos hired Dave Wurtz and Daniel Guggenheim on July 21 to lead the beleaguered company’s regulatory, quality and compliance departments.

A federal judge refused AstraZeneca’s request to temporarily ban companies from selling generic versions of rosuvastatin calcium (Crestor), Bloomberg reports. Barring an appeal, companies will be able to sell cheaper versions of the blockbuster medication, which accounted for more than $5 billion in sales.

Novartis plans on spending an additional $200 million this year to boost sales of sacubitril/valsartan (Entresto), the company’s twice-daily oral medication to treat patients with heart failure.